2020
, 2020
27 October
vaccination
ation
G Collabor
A
NIT
behalf of the EU/EEA
on
27 October 2020
ialogue meeting held 23 October,
d
State of play with national strategies in the EU/EEA and the UK –
HSC Meeting,
tee ork
rs
bers
2018
2
to w ECDC
mbe
em )
ners
29)
m
in
=2
e me (n=
ve (n
5 MS
Key part
Activ
Passi
authorised in
Steering Commit from closely with Secretariat
formed
methodology
oups vaccines
on
ature evidence-based
EE
FI
DK
FR
DE
CZ
the liter
GR
WG N
CY
Technical Advisory Gr
HU
HR
IS
**
BU
9
IE
sation
WG 3
-1
group
BE
following standard
COVID
C
IT
evidence in
D
AT
etariat
EC
LI
ety,
*
UK
secr
Immuni
LV
saf
WG 2 FLU child
SE
LT
ES
and
LU
SI
lt
MT
SK
WG 1 FLU adu
NL
RO
NO
PT
PL
eness
EU/EEA National
fectiv
, ef
or
y and summarize scientific
EU
ure f
at
E)
D
ficacy
liter ety for s (
ibuting
n
to identif
iew of and saf vaccine
ation between
O /HQ
is
ropean
O
-19
WH
ic rev
Eu mmissio
at eness ID
EU incl. ef
Co
EUR RNN/GNN
alth is contr
iv
He em fect
cy
st
d COV
oint
Collabor Focus the
, ef ise
EU/EEA NITAG Collaboration
ropean
ction on
Public
Eu Medicines Agen
EC/J A accination
ive sy
•
•
V
K
ficacy
*U ** L ef author
3
in
prioritise
will be
to
accinated
der
systems
plans
under
and acceptance
be v
or
to
ed…
er
eness
in short supply?
currently
are
deliv
monitoring ectiv
y groups
eff
vaccines
and by whom in
will be
ety,
vaccines
ed
-specific
for priorit
, saf
oduct age
EU/EEA MS and the UK
when
accines
or COVID-19
een consider
how v
how pr
ailable?
e b
on
on
plan f
accine cover
accination?
ate: 21/31
recommendations the campaigns
for v
already av
of
ormation
ormation
will be/hav
deployment
eloped
oups
document v
of country vaccination preparedness
phases
gr
ovide inf
ovide inf to
Response r
accine
evidence get
e you dev
Is a v development or
Hav the initial
What the tar
Please pr
Please pr organised
Overview collected
•
•
•
•
•
4
of
all
for
almost
unknowns;
y
plans
ailable in
the man
av
to
be
recommendations
due
meeting;
interim
preparedness
eloped
dialogue
in all countries
dev
the
ess
ogr
plans were mentioned to
in pr
further and
vaccination
e come vaccinated first:
countries attending
be
er, it is still work
ul hav
Vaccination preparedness the 21/31
Howev
A handf groups to
Availability of
•
•
•
5
ailable
comorbidities,
av
ers
due to
workers
work
home
determined)
disease
to be
erent definitions
social care
y
based
and care
diff
age
riorit
home
(p
e facilities/institutions
health and
severe COVID-19 car
in a care and
social workers,
advice is entirely
adults
mentioned
and
of the population
65+)*
long-term
interim
Older All those 80+ All those 75+ All those 70+
All those 65+ All those 60+ All those 55+
All those 50+ Rest
(60+,
•
•
•
•
•
•
•
•
•
with higher risk of
*UK
esidents in
care workers
being r
Health
Older people
Individuals or
Priority groups
•
•
•
at
6
accine as well
oups
(e.g. on
vaccines
e on gr
reported v
data
of
atur
liter
ears will accept
including acteristics
>64 y
om the
fr COVID-19;
vaccination;
country specific
, char
of
3 studies, oup
due to
gr
individuals
ormation
of
for prioritisation and
impact of
get
analysis inf
om phase tar
and death
et groups when needed
fr
data, y) and
ansparency;
(only 54%
targ
eillance
disease
of
ormation
mortalit
inf
airness, tr
be considered
modelling assessing
severe
Finland)
efficacy by age and y;
assessments
justice, f
y,
ety and vailabilit
Mathematical
Vaccine-specific saf as a
Epidemiological surv hospitalization and higher risk of
Equit
Acceptance vaccination in
Evidence to reprioritisation
•
•
•
•
•
7
seasonal
for
chain
additional
COVID-19 or
vaccination
and cold about need f
ery services
COVID-19
deliv
ansport ormation potential
e inf
incl. out of
the
age, tr
,
es oll
stor as mor
servic
d
for the r
ailable i.e.
ery
vaccine assesse
deliv
that be
chain.
become av e cold
and structures
accination
esponded
atur
will need to acteristics
vaccines
existing v
countries r ements
a low temper
Use of influenza plans;
Some requir vaccine char ultr
Logistical considerations
•
•
8
countries.
erse
groups
-2
adv
ocus
for COVID-19
possible
in all EU/EEA
SARS-CoV
y
vestigated.
registries
for
in
surveys/f
egistries:
be
rates
place:
available
indemnif
immunisation
in
ound
onic
law to
Acceptance in
immunisation r
age
detection
a
ackgr
ed
onic
cover
y. B
ral populations to
*
studies/
ad hoc electr
for
signal
in
electr
gene
propos
in
for coverage, safety,
using
systems
oduct liabilit
est
pr
assessed
inter
ently considering
be
erage
ond
curr
or
ety reporting with
, MoH in
special
eloping
outine saf
ents of
ectiveness to
monitoring:
Monitoring cov
Countries with other
R
In October
vaccinated bey
ev
Eff
Monitoring system effectiveness and acceptance
•
•
•
•
*Countries dev vaccine